Shots:
- Ionis has reported topline P-III (ESSENCE) trial data assessing olezarsen (50mg: 276 pts or 80mg: 832 pts, SC, Q4W for 12mos.) vs PBO (n= 369) in 1,478 adults with mod. hypertriglyceridemia (fasting TG ≥150mg/dL to <500mg/dL) with or at risk of ASCVD
- Trial met its 1EP with significant PBO-adjusted TG reductions of 61% (80mg) & 58% (50mg) at 6mos., plus achieved all key 2EPs, with most pts reaching TG levels of <150mg/dL; data to be presented at a future conference
- Additionally, Ionis will report data from P-III (CORE & CORE2) trials of olezarsen by Q3’25, with sNDA submission expected by year-end for the treatment of sev. hypertriglyceridemia
Ref: Businesswire| Image: Ionis | Press Release
Related News:- Ionis Partners with Sobi for Olezarsen to Treat Familial Chylomicronemia Syndrome (FCS) & Severely Elevated Triglycerides
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
